Hybio Pharmaceuticals and KuCoin have reached a strategic cooperation to explore the innovative drug RWA project
August 4, 2025
Source: drugdu
77
According to Hybio Pharmaceutical, on August 4, Hybio Pharmaceutical and digital asset platform KuCoin officially signed a letter of intent for strategic cooperation. The two parties intend to jointly explore and promote the first " innovative drug" in mainland China in Hong Kong. This is a pilot project for tokenizing RWA (Real World Asset) with the future income rights of R&D as the underlying asset. According to the agreement, Hybio Pharmaceutical will use its technology accumulation and R&D pipeline in the field of GLP-1 peptide blockbuster drugs as the underlying asset, and KuCoin will leverage its blockchain The advantages in technology, RWA full-process solutions and global compliance resources provide the project with integrated support for on-chain mapping, asset tokenization, transaction matching, and profit distribution.
https://finance.eastmoney.com/a/202508043475115419.html
Copyright©2025 Ddu. All rights reserved.
Read more on
- The application for marketing authorization of trivalent influenza virus split vaccine has been accepted October 8, 2025
- Walvax Biopharma’s vaccine receives Jordanian Drug Registration Certificate, marking a key step forward in its Middle East market expansion. October 8, 2025
- Zhifei Bio’s independent product, influenza virus split vaccine, has obtained a drug registration certificate October 8, 2025
- Antihypertensive and lipid-lowering drugs show efficacy against steatotic liver disease October 7, 2025
- Large-scale analysis offers insights into sporadic nature of chikungunya virus outbreaks October 7, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
